GlassScriptPhysician profile
Michael Yc Tso
NPI 1578592184
$2,689.74
in general payments reported to CMS, 2019-2025
27 companies · $434 in 2025
The $434 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $268 · 2020: $95.08 · 2021: $190 · 2022: $337 · 2023: $693 · 2024: $673 · 2025: $434.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,800.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,800.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $443.43 | 2022-2025 | Azstarys |
| Abbvie INC. | $299.15 | 2023-2025 | Vraylar |
| Takeda Pharmaceuticals U.S.A., INC. | $225.50 | 2019-2023 | Trintellix |
| Lundbeck LLC | $217.31 | 2019-2025 | Rexulti |
| Axsome Therapeutics, INC. | $141.11 | 2023-2025 | Auvelity, Sunosi |
| Supernus Pharmaceuticals, INC. | $135.52 | 2021-2025 | Qelbree, Qelbree |
| Vanda Pharmaceuticals INC. | $129.13 | 2019-2025 | Fanapt, Hetlioz |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $126.75 | 2022-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $120.01 | 2019-2023 | Rexulti |
| Janssen Pharmaceuticals, INC | $110.07 | 2022-2024 | Spravato |
| Teva Pharmaceuticals USA, INC. | $95.05 | 2023-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Shire North American Group INC | $80.40 | 2019 | |
| Alkermes, INC. | $68.92 | 2022-2024 | Lybalvi |
| Ironshore Pharmaceuticals INC. | $57.94 | 2023-2024 | Jornay Pm |
| Almatica Pharma LLC | $51.40 | 2021-2023 | Loreev Xr, Sertraline Hcl |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $50.69 | 2025 | Jornay Pm |
| Tris Pharma INC | $50.41 | 2019-2024 | Dyanavel Xr |
| Bausch Health US, LLC | $48.60 | 2021-2024 | Wellbutrin, Aplenzin |
| Sunovion Pharmaceuticals INC. | $42.62 | 2022 | |
| Neurocrine Biosciences, INC. | $42.01 | 2025 | |
| Jazz Pharmaceuticals INC. | $37.17 | 2019-2020 | |
| Alfasigma USA, INC. | $25.49 | 2020-2022 | |
| Biogen, INC. | $23.39 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $21.91 | 2025 | Cobenfy |
| Avanir Pharmaceuticals, INC. | $16.14 | 2019 | |
| Adlon Therapeutics L.P. | $15.22 | 2019 | |
| Owp Pharmaceuticals, INC. | $14.40 | 2023 | Subvenite, Lamotrigine |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Tso listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.